A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

The efficacy and safety of risperidone long-acting injectable (LAI) for preventing recurrence of mood episodes in patients with bipolar I disorder was evaluated in a randomized, placebo-controlled study. After a 12-week open-label period with risperidone LAI (n=560), patients who did not experience...

Descripción completa

Detalles Bibliográficos
Autores Principales: Vieta, Eduard, Montgomery, Stuart, Hatim Sulaiman, Ahmad, Huberlant, Benedicte, Martinez, Lupe, Schreiner, Andreas, Cordoba Rojas, Rodrigo Nel
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Elsevier 2012
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/26389
https://doi.org/10.1016/j.euroneuro.2012.03.004